Merit Progression Sample Clauses

Merit Progression. 5.2.1.1 The salary scale provides movement to salary steps above the automatic steps that provide employees with a pathway for career development within their professional role. Employees on these steps will be required to function at an advanced level. The process providing for movement through these steps is set out in progression criteria for Social Workers agreed between the parties.
AutoNDA by SimpleDocs
Merit Progression. Waitemata District Health Board (WDHB), Auckland District Health Board (ADHB), and Counties Manukau Health (CMH) supports the development and implementation of criteria which provides clerical and administrative staff with an opportunity to progress through the merit salary scales in a structured, supported, flexible and achievable way. Progression from the top automatic step in the salary scale to the first merit step, and to subsequent merit steps, is dependent on the achievement of mutually agreed Merit Objectives. The procedure outlined in the “CMDHB/ADHB/WDHB/PSA Clerical and Administration Employees Merit Progression Guidelines” and the “NDHB/PSA Merit Progression Guidelines” will be followed. These Guidelines are available on each DHB’s intranet. Managers and employees should familiarise themselves with the guidelines prior to undertaking the process. If at any point of the Merit application process the guidelines are not followed either the manager or employee can escalate the application to the one up manager and/or relevant Human Resources representative, and/or PSA representative.
Merit Progression. The work stream will address the and a written report produced for the parties’ consideration no later than December 2014. The parties shall meet to discuss the report and progress matters on February 10, 2015 (unless otherwise agreed between the parties).
Merit Progression a) There are salary steps above the automatic steps that provide employees with a pathway for career development within their professional role. Employees on these steps will be required to function at an advanced level. The process providing for movement through these steps is known as Career and Salary Progression (CASP) and is available on the DHB intranet.
Merit Progression. (a) The minimum salary increase shall be $1,300.
Merit Progression. 13.1 Employees may apply for progression to a higher salary step at any time, but not more frequently than once a year unless otherwise agreed by both parties.
Merit Progression. The merit progression process will be based on the principles of Transparency, Consistency and Fairness. Merit steps are linked to the number of top salary steps as outlined in the DHB specific schedules. Employees will be eligible for progression to the appropriate merit step either; • one year after reaching the top ‘automatic’ salary or • one year after reaching any merit step below the top step in their salary band The Merit step acknowledges an employee who is continually performing above the expectations of the job and who consistently demonstrates good behavioural standards and role models the values of the DHB.
AutoNDA by SimpleDocs
Merit Progression. 2.2.1 Progression to the Merit step may occur when Employees have completed one year’s service on step three (3), are performing competently in all aspects of their jobs and are contributing one or more of the following:
Merit Progression. 11.3.1 Progression above step 5 shall be according to the TDHB Dietitian Progression Criteria. During the term of the document the parties will meet to discuss and agree a new Career Progression Criteria that will form part of the SECA. This work will be completed by the end of May 2019 so that employees have an agreed process to apply for merit progression.

Related to Merit Progression

  • Progression For progression for all classifications under this agreement, refer to Schedules A to D.

  • Wage Progression (a) Employees within their position classification will progress from the "start rate" to the "one year rate" and so on, on the basis of eighteen hundred (1800) hours paid by the Employer at the "start rate" to the "one year rate" and so on. Hours for which the employee receives WSIB as a result of a work related injury while in the employ of the Employer shall be considered hours paid for the purposes of computing eligibility to progress to the next higher rate within their position classification.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).

  • Salary Progression 1. For the purposes of determining annual progression from one step to the next, each teacher’s performance will be assessed annually against the appropriate professional standards.

  • Incremental Progression Three (3) Year Trained Teacher - Professional Development

  • Pilot Programs The Employer may develop voluntary pilot programs to test the acceptability of various risk management programs. Incentives for participation in such programs may include limited short-term improvements to the benefits outlined in this Article. Implementation of such pilot programs is subject to the review and approval of the Joint Labor-Management Committee on Health Plans.

  • Orientation Program The Company will allow a designated representative of the Local or Bargaining Unit up to one (1) hour per calendar month for the purpose of conducting the Communications, Energy and Paperworkers Union New Members’ Orientation Program. Such meetings will be conducted during the probationary period of employees, and will be held on Company premises. Employees participating in Orientation Program meetings during their normally scheduled working hours will not suffer loss of pay at their regular rate. Orientation Program meetings will be scheduled by Management and a Management representative may attend as an observer.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Drug Testing (A) The state and the PBA agree to drug testing of employees in accordance with section 112.0455, F.S., the Drug-Free Workplace Act.

Time is Money Join Law Insider Premium to draft better contracts faster.